Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...

SAN DIEGO – The VARSITY study results showed that clinical and endoscopic outcomes of Entyvio treatment were superior to those of Humira in moderately to severely active ulcerative colitis at 1 year, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

OSAKA, Japan, Oct. 16, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in specific ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...

A study in Inflammatory Bowel Diseases used a novel simulation model to assess the optimal treatment positioning for patients with moderately to severely active ulcerative colitis and to predict ...

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...

Coming as little surprise after an FDA advisory panel backed Entyvio (vedolizumab) for treatment of severe ulcerative colitis and moderate to severe Crohn's disease, Takeda Pharmaceutical Co. Ltd.'s ...

This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,. This information is exclusively for Payer Formulary Committees or other similar entities (groups of individuals that evaluate ...